Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart failure

Novo taps behavioural change for diabetes programme’s re-launch

Adds health coach function to Cornerstones4Care

- PMLiVE

Novo Nordisk’s Klaus Henning Jensen on trends in medical affairs

PMLiVE speaks to the head of clinical, medical and regulatory for Novo in the UK and Ireland

- PMLiVE

Novo Nordisk profits up 4%, buoyed by Victoza and Levemir

But expects net loss for 2014 from currency impact

- PMLiVE

US investigates Novo Nordisk manufacturing issues

Issues subpoena related to insulin plant in Kalundborg, Denmark

- PMLiVE

Regeneron top science employer, says survey

Ranked highest for third year in a row

- PMLiVE

Novo Nordisk’s Xultophy diabetes combo approved in Europe

Once-daily injection combines the firm's Tresiba and Victoza

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Novo Nordisk gives up on inflammation R&D

Follows disappointing trial results for arthritis drug

- PMLiVE

Novo Nordisk debuts diabetes combo in Mexico

Requires fewer daily injections than current insulin treatment

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

- PMLiVE

Team Novo Nordisk to compete in The Tour of Britain

World’s first all-diabetes pro-cycling team will cycle over 1,300km in eight days

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links